Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bg, Stultz"'
Publikováno v:
Europe PubMed Central
Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we exa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7ba907b7784b6b4d5fdacd97ecb197da
https://pubmed.ncbi.nlm.nih.gov/10919663
https://pubmed.ncbi.nlm.nih.gov/10919663
Autor:
Stultz BG; Division of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA., Hursh DA; Division of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. deborah.hursh@fda.hhs.gov.
Publikováno v:
Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2019; Vol. 1891, pp. 75-89.
Autor:
Hursh DA; Division of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. deborah.hursh@fda.hhs.gov., Stultz BG; Division of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Publikováno v:
Advances in experimental medicine and biology [Adv Exp Med Biol] 2018; Vol. 1046, pp. 41-58.
Autor:
Thomas JT; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States., Eric Dollins D; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States., Andrykovich KR; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States., Chu T; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States., Stultz BG; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States., Hursh DA; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States., Moos M; Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, U.S. Food and Drug Administration, Silver Spring, United States.
Publikováno v:
ELife [Elife] 2017 Mar 21; Vol. 6. Date of Electronic Publication: 2017 Mar 21.
Autor:
Hursh DA; a Division of Cell and Gene Therapies , Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring , MD , USA., Stultz BG; a Division of Cell and Gene Therapies , Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring , MD , USA., Park SY; b Ischemic/Hypoxic Disease Institute , Department of Physiology , Seoul National University College of Medicine , Seoul , Republic of Korea.
Publikováno v:
Fly [Fly (Austin)] 2016 Oct; Vol. 10 (4), pp. 195-203. Date of Electronic Publication: 2016 Jul 06.
Autor:
Rovira Gonzalez YI; Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Lynch PJ; Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: Patrick.Lynch@fda.hhs.gov., Thompson EE; Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Stultz BG; Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA., Hursh DA; Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: Deborah.Hursh@fda.hhs.gov.
Publikováno v:
Cytotherapy [Cytotherapy] 2016 Sep; Vol. 18 (9), pp. 1114-28. Date of Electronic Publication: 2016 Jul 12.
Autor:
Stultz BG; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., McGinnis K; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Thompson EE; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Lo Surdo JL; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Bauer SR; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Hursh DA; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: deborah.hursh@fda.hhs.gov.
Publikováno v:
Cytotherapy [Cytotherapy] 2016 Mar; Vol. 18 (3), pp. 336-43. Date of Electronic Publication: 2016 Jan 15.
Autor:
Park SY; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993 BK21PLUS Biomedical Science Project, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea., Stultz BG; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993., Hursh DA; Division of Cell and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993 deborah.hursh@fda.hhs.gov.
Publikováno v:
Genetics [Genetics] 2015 Dec; Vol. 201 (4), pp. 1411-26. Date of Electronic Publication: 2015 Oct 23.
Autor:
Stultz BG; Division of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA., Park SY, Mortin MA, Kennison JA, Hursh DA
Publikováno v:
Developmental biology [Dev Biol] 2012 Sep 15; Vol. 369 (2), pp. 362-76. Date of Electronic Publication: 2012 Jul 21.
Autor:
Sen A; Cell and Tissue Therapy Branch, Center for Biologics, Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA., Stultz BG, Lee H, Hursh DA
Publikováno v:
Developmental biology [Dev Biol] 2010 Jul 01; Vol. 343 (1-2), pp. 167-77. Date of Electronic Publication: 2010 Apr 18.